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Background: The primary aim of this prospective, multicentre feasibility study was 
to determine whether the biopsied axillary node can be marked using black carbon 
dye and successfully identified at the time of surgery. 
Methods: We included patients undergoing needle biopsy of the axillary node. The 
biopsied node was tattooed at the time of needle biopsy (fine needle aspiration or core 
biopsy) or at a separate visit with black carbon dye (Spot™ or Black Eye™). 
Participants underwent primary surgery or neoadjuvant chemotherapy (NACT) and 
axillary surgery (SNB or ALND) as per routine care. 
Results: 110 patients were included. Median age of the women was 59 (range 31 to 
88) years. 48 (44%) underwent SNB and 62 (56%) ALND. Median volume of dye 
injected was 2.0 ml (range 0.2-4.2). Tattooed node was identified intraoperatively in 
90 (82%) patients. The identification rate was higher (76 of 88, 86%) in the primary 
surgery group compared with NACT (14 of 22, 64%) (p=0.03). Of those undergoing 
NACT, the identification rate was better in the patients undergoing SNB (3 of 4, 75%) 
compared with ALND (11 of 18, 61%) (p>0.99). The tattooed node was the sentinel 
node in 78% (28 of 36) patients in the primary surgery group and 100% (3 of 3) in the 
NACT group. There was no learning curve for surgeons or radiologists. The 
identification rate did not vary with timing between dye injection and surgery 
(p=0.56), body mass index (p=0.62) or volume of dye injected (p=0.25). 



















We have witnessed de-escalation of axillary surgery in the last two decades. Sentinel 
node biopsy (SNB) has become the procedure of choice for axillary staging in patients 
who are clinically node negative at presentation irrespective of whether they undergo 
primary surgery or neoadjuvant chemotherapy (NACT). For patients with needle 
biopsy proven positive nodes at presentation, axillary lymph node dissection (ALND) 
is generally indicated if they undergo primary surgery. However, a subgroup with low 
volume nodal disease based on number of abnormal nodes on axillary ultrasound and 
tumour size[1] can be offered sentinel node biopsy rather than ALND. Patients found 
to have less than 3 involved nodes on SNB may be spared ALND[2;3]. Alternatively, 
NACT may be given to suitable patients to downstage the axilla followed by SNB to 
assess the residual tumour burden.  
 
In both scenarios, the concern is that the biopsied node with metastases may be left in 
the axilla at SNB. For patients undergoing primary surgery, Nathanson et al.[4] 
reported a 78 per cent concordance between the biopsied node and sentinel node. The 
false-negative rate of SNB after NACT in cN1 patients was studied in Z1071[5] and 
SENTINA[6] trials and found to be more than 10%. A recent meta-analysis showed 
that the combination of SNB with removal of the marked involved node following 
NACT reduces the FNR to less than 5%[7] (targeted axillary dissection, TAD). 
 
There are a number of techniques being investigated to mark the involved node and 
then visualise it intra-operatively. A clip can be placed in the needle biopsy positive 
node and x-ray of the specimen be performed at SNB to ensure that the clipped node 
is removed. The clipped node can be marked using a wire to guide the surgeon before 
surgery[8]. However this technique has limitations as nodal shrinkage with 
chemotherapy may result in clip displacement and post NACT, the clip cannot be 
visualised on ultrasound scan in around 30% patients[9]. Alternatively, the involved 
node can be marked using black carbon dye[10-12], magnetic seed (Magseed)[13],  
reflector (SAVI Scout®)[14], radiofrequency tag (LOCalizer™)[15] or radioactive 
iodine seed (I125)[16]. The black carbon dye is less expensive and single-centre 
studies have reported more than 90% identification rate of the tattooed node intra-
operatively. However, the technique remains to be standardised and tested in 





The primary aim of this prospective, multicentre feasibility study was to determine 
whether the biopsied node can be marked using black carbon dye and successfully 
identified at the time of surgery. The secondary aims were to determine the 
concordance between the tattooed node and sentinel node, migration of black dye into 
other nodes and standardise the technical aspects of the technique.  
 
Methods 
This was an investigator-led multicentre cohort study done at 5 centres in the UK 
(Derby, Burton-on-Trent, Leicester, Leeds, Plymouth). The study protocol was 
approved by the South West - Exeter Research Ethics Committee (REC reference: 
18/SW/0097) and local research and development offices of participating institutions. 
All participants provided written informed consent. The study complies with the 
principles of the Declaration of Helsinki.  
Individuals were eligible for inclusion if they were aged ≥ 18 years, had early stage 
(stage I-IIIA) unifocal or multifocal invasive breast cancer with abnormal looking 
lymph node/s on preoperative ultrasound scan at presentation and undergoing needle 
biopsy of the lymph node (fine needle aspiration (FNA) or core biopsy). Individuals 
were excluded if they had skin tattoo in the drainage area of the axilla, were not 
undergoing axillary surgery or unfit for axillary surgery. Participants underwent 
primary surgery or NACT and axillary surgery (SNB or ALND) as per routine care.  
 
Carbon dye tattooing 
The biopsied node was tattooed at the time of needle biopsy (FNA or core biopsy) or 
at a separate routine visit to the hospital. The black carbon dye (Spot™ or Black 
Eye™ (Omnimed Limited™, Winchester, England)) was injected both in the cortex 
of the node and the perinodal tissue under ultrasound guidance by a breast radiologist 
or radiographer. Additionally, in the initial 8 cases the dye was injected in the needle 
tract but this was abandoned as it resulted in generalised black staining of the axillary 
contents as observed at the time of surgery.  The protocol was not prescriptive about 
the volume of injection as it was intended that the data generated from this study 
would inform the recommended volume for future practice. The volume of injection 
was recorded and varied depending on the node size and the operator. If there were 







Participants who were node negative on needle biopsy underwent sentinel node 
biopsy (SNB), while those with involved node/s underwent axillary lymph node 
dissection (ALND) as per local standard of care. Sentinel node biopsy was performed 
as per local protocol. The protocol did not dictate the injection technique or tracer/s to 
be used. Sites were allowed to use a combination of isotope and blue dye or a single 
tracer (isotope or blue dye). Patients undergoing ALND did not undergo SNB first at 
the same operation. The surgeon identified and removed the tattooed lymph node/s at 
the time of planned axillary surgery (Figure 1). 
 
Pathology 
All lymph nodes were examined and reported according to predefined local practice 
that met the UK Royal College of Pathologists guidelines: nodes smaller than 5 mm 
were bisected, larger nodes were sliced at 2-mm intervals, and single sections 
assessed using haematoxylin and eosin staining. Immunohistochemical staining was 
not required, but was used selectively to characterize isolated tumour cells, suspicious 
or micrometastatic disease, in accordance with local protocol.  
 
Outcomes 
The primary outcome measure was identification rate of tattooed node at the time of 
axillary surgery. Secondary outcomes were concordance between tattooed node and 
sentinel node (tattooed node removed as part of sentinel node biopsy) and migration 
of dye into other nodes. 
 
Additionally, the effects of body mass index, the timing of the injection of dye and 
surgery, volume of dye injected and case volume per surgeon and radiologist 
performed on identification of tattooed node were assessed. Potential pitfalls of 
tattooing such as diffusion of the black dye in the axillary contents and skin 
discoloration were documented.  
 
Data collection and statistical analysis 
Study data were collected and managed using REDCap electronic data capture tools 
hosted at Royal Derby Hospital, Derby. Continuous variables were summarised using 





Comparisons of continuous variables across binary groups were performed using a 
Wilcoxon rank sum test. A Spearman’s rank correlation was used to assess the 
relationship between two continuous variables. Categorical variables are reported with 
frequencies and percentages and compared across groups using a chi-squared test, or a 
Fisher’s exact test if small numbers. A stepwise logistic regression model was used to 
investigate the predictors of identification of the tattooed node. All analyses were 
performed using the SAS statistical package, version 9.4. Significance was 
determined at the 5% level. 
This study is registered with ClinicalTrials.gov, number NCT03640819. 
 
Results 
Between April 2018 and July 2019 a total of 110 women with breast cancer who had 
needle biopsy of the axillary lymph node were eligible for inclusion in the study. 82 
patients underwent primary surgery and 28 received NACT. Of the 28 patients that 
had NACT, 6 underwent SNB before NACT and therefore were included with the 82 
patients that did not receive NACT for analyses.  
 
Patient demographics, type of breast and axillary surgery and tumour characteristics 
are shown in Table 1. All women underwent axillary surgery (SNB or ALND) and all 
but two women had breast surgery (breast-conserving surgery or mastectomy).The 
median age of the women was 59 (range 31 to 88) years. 48 of 110 (44%) underwent 
SNB and 62 (56%) ALND. SNB was performed using a combination of isotope and 
blue dye in the most patients and the sentinel lymph node was identified in 46 of the 
48 (96%) who had a SNB. 61 of the 110 (55%) patients were node positive at 
presentation (43 of 88 (49%) in the primary surgery group and 18 of the 22 (82%) in 
the NACT group. 
 
Tattooing results 
Table 2 shows the results of carbon dye tattooing. The dye was injected in the node at 
the time of needle biopsy in 75 of 110 (68%) and at a separate visit after the results of 
the biopsy in 35 (32%). The median volume of dye injected was 2.0 ml (range 0.2-
4.2). The dye was injected in the cortex and perinodal tissue in 102 patients and 





and surgery was 28 days (IQR 19-34) for primary surgery and 199 days (IQR 167-
225) for NACT group.  
 
Tattooed node was identified in 90 of 110 (82%) patients. The identification rate was 
81% (39 of 48) in patients who underwent SNB and 82% (51 of 62) for ALND; 
p=0.89. Patients undergoing SNB where the tattooed node was not identified had ≤2 
nodes removed. The identification rate was significantly higher (76 of 88, 86%) in the 
primary surgery group compared with NACT (14 of 22, 64%); p=0.03. Of those 
undergoing NACT, the identification rate was not significantly better in the patients 
undergoing SNB (3 of 4, 75%) compared with ALND (11 of 18, 61%); p>0.99. Of 
those undergoing SNB where the tattooed node was identified, the tattooed node was 
the sentinel node in 78% (28 of 36) of patients in the primary surgery group and 100% 
(3 of 3) in the NACT group; p>0.99. The presence of diffuse black staining was seen 
in 4 of these 31 (13%) patients were the tattooed node was the sentinel node.   
 
The median number of tattooed nodes identified by the surgeon was 1 (range 0 to 6) 
and on histology was 1 (range 0 to 8) (Figure 2). There was diffuse black staining of 
axillary tissue in 22% of patients (19 of 88) in the primary surgery group, which was 
significantly less than  55% (12 of 22) in the NACT group (p=0.002).  
 
There were no allergic reactions reported but one patient reported skin discoloration 
in the axilla.  
 
Other factors affecting identification rate of tattooed node 
Volume of injected dye  
The volume of dye used for those where the tattooed node was identified was similar 
to that used where the tattooed node was not identified (median 2.0 (IQR 1.2-2.9) 
versus median 2.0 (IQR 0.3-2.5), p=0.25). The volume of dye injected was not 
correlated with the number of tattooed nodes identified and removed (Spearman’s 
correlation p=0.59) .The volume of dye injected was not significantly associated with 
the presence of diffuse black staining (median 2.2 (IQR 1.8-3.0) compared with the 






Following these analyses, we injected varying volumes of dye ex-vivo in lymph 
glands of different sizes (Figure 3) to determine the optimum volume for injection. 
We found that a volume of 0.2 to 0.4 ml is sufficient to stain the lymph node. Even 
with this small volume, the dye spills into adjacent perinodal tissue and therefore 
separate injection either around the node or in the tract is not required. 
 
Timing of injection 
The median time between the dye injection and surgery where the tattooed node was 
identified was 30 days (IQR 21-42), which was similar to the median of 36 days for 
those where the tattooed node was not identified (IQR 24-165); p=0.36. The timing 
was also not significantly different between these groups for those having NACT 
(median 203 (IQR 172-225) versus median 183 (IQR 163-218) respectively, p=0.78) 
and also for those in the primary surgery group (median 28 (IQR 16-34) versus 
median 26 (IQR 14-34), p=0.59). However, the median time between the dye 
injection and surgery was significantly longer for those with diffuse black staining 
(median 59; IQR 22-183) compared to those without black staining (median 29; IQR 
20-34, p=0.01). 
 
Body mass index (BMI) 
The BMI for the patients where the tattooed node was identified was not significantly 
different to the BMI for those where the tattooed mode was not identified (median 
BMI 29.3 (IQR 25.0-32.7) versus median 28.9 (IQR 25.1-34.4), p=0.62). 
 
Multivariate analysis 
Logistic regression identified primary surgery or NACT as the only independent 
significant predictor of the identification of the tattooed node (Odds ratio 3.26; 95% 
CI 1.02-10.41, p=0.05). 
 
Surgeon learning curve  
Of the 20 surgeons, the median number of surgeries conducted was 4, minimum 1 and 
maximum 20. A waterfall plot of the percentage of cases where the tattooed node was 
successfully identified did not show a learning curve (Figure 4). Ten surgeons were 
able to identify the tattooed node in all surgeries. Only 4 (20%) out of the 20 surgeons 





the only ones not to identify the tattooed node on the very first surgery. For the 
remaining six surgeons with an identification rate between 63% and 89%, it didn’t 
seem to be the first or second surgeries where they had problems identifying the 
nodes. 
 
Radiologist learning curve 
Thirteen radiologists participated in the study. The tattooed node was identified for all 
their patients for 5 radiologists. 
The first failed identification of the tattooed node was the first injection for 4 
radiologists, whereas it was the 3rd, 7th, 8th and 12th for the remaining 4 radiologists. 
Therefore, for the majority there was an apparent learning curve. 
 
Discussion 
The results with carbon dye tattooing to mark the axillary lymph gland in patients 
with breast cancer were encouraging from single centre studies[10-12] (sample size 
20 to 75) leading us to conduct this multicentre feasibility study to evaluate the 
technical aspects of the technique. Using the carbon dye to mark the node and identify 
it during surgery, we overall found the tattooed node in 82% of patients. In clinical 
practice, the technique will be used to mark the involved node in patients undergoing 
primary surgery and sentinel node biopsy or targeted axillary dissection (TAD) after 
NACT. Therefore, restricting to patients undergoing SNB, we identified the tattooed 
node in 82% patients in primary surgery group and 75% after NACT.  
 
The results are less favourable when compared with 93.7% identification rate in 
patients undergoing primary surgery by Choy et al.[10] and post NACT identification 
rates of 94.6% by Natsiopoulos et al.[11], and 100% by Choy et al.[10] and Park et 
al.[12].This can be attributed to several reasons. These studies were single-centre in 
contrast to our multicentre study. Additionally, the median volume of dye injected 
was more in our study compared to previous studies. There was background black 
staining of axillary tissue in 22% patients in the primary surgery group and 55% 
patients in the NACT group. The data suggest that diffusion of dye is more prominent 
with increasing time interval between injection of dye and surgery. This may have 
compromised the identification rate of the tattooed node.  One of our aims was to 





black staining of axillary tissue, identification rate of tattooed node or number of 
tattooed nodes identified intra-operatively. From ex vivo work, we recommend a 
volume of 0.2 to 0.4 ml to mark the lymph node (Figure 4). The dye should not be 
injected around the node or in the tract to avoid diffusion into the axillary tissue and 
skin discoloration.  
 
The success rate in identifying the tattooed node did not vary with body mass index. 
Additionally, we did not find a learning curve for surgeons or radiologists in the 
study. This is not surprising as all participating surgeons and radiologists were breast 
specialists and experienced in the technique of sentinel node biopsy and node biopsy. 
This is reassuring as the technique has the potential for widespread adoption in 
clinical practice.  
 
This study will lead to improved understanding of site and volume of injection, and 
factors that may affect identification of tattooed node. Multivariate analyses showed 
that identification rate of tattooed node is significantly less after NACT compared 
with primary surgery. These results mirror the early findings of decreased sentinel 
node identification rate after NACT.  
 
In clinical practice, this technique can be used alone or in combination with clip 
placement. Based on the ex vivo study, we recommend that 0.2 to 0.4 ml of black dye 
is injected in the cortex at the time of FNA or core biopsy or after the biopsy results at 
a separate visit (both approaches are feasible as shown in this study). Alternatively, to 
reduce the risk of diffusion of the dye into surrounding tissues with time, a clip can be 
placed in the involved node before NACT and the clipped node/clip can be tattooed 
before surgery for identification intra-operatively. The surgeon can stop after 
confirming removal of clip on specimen x-ray in case of multiple black nodes. This 
technique can be used in other settings such as to mark the non-palpable node in 
patients undergoing excision biopsy of the axillary lymph node.  
 
There are other techniques that can be used to offer a targeted approach e.g. placing a 
radioactive iodine seed[16], magnetic seed (Magseed)[13], reflector (radar 
technology, SAVI Scout®) or radiofrequency tag (LOCalizer™) to mark the 





£10000, apart from approximately £300 per patient cost for the implant and the 
implant can potentially migrate. Radioactive iodine seed has the disadvantages of 
limited availability, regulatory issues and decay in signal with time and therefore may 
be difficult to detect if placed in the node before NACT. Magnetic seed can interfere 
with MRI scan and there is an additional cost for disposable non-metal instruments 
during surgery. The size of the reflector (SAVI Scout®) or radiofrequency seed 
(LOCalizer™) is more than 10 mm which may be a limitation when marking small 
nodes[15].   
 
The carbon dye technique has the advantage of low cost (around £10 for carbon dye 
per patient) and absence of need for special equipment. This technique will 
particularly be useful in countries with limited resources. However the identification 
rate is no different to that reported in the initial studies with blue dye guided sentinel 
node biopsy. We anticipate this to improve as the technique evolves in the future. 
Other disadvantages are black staining of the axillary tissue and dye migration in 
some patients although these risks can be minimised by restricting the volume of 
injection to 0.2 to 0.4 ml. Importantly, this technique has limited utility in patients 
who have skin tattoos in areas draining to the axillary nodes.  
 
The limitations of this study are the small number of patients who underwent SNB 
following NACT and we did not evaluate the false negative rate of tattooed node as 
node-positive patients underwent ALND (as per local standard of care) rather than 
SNB or targeted axillary dissection. Other limitations are varying volume of dye 
injected and two different black dyes used in the study.  
 
On the basis of the results of this study, it is feasible to mark the biopsied node with 
black dye and successfully identify it intra-operatively. Modifications of the 
technique, such as injecting the dye in the cortex alone, restricting the volume to 0.2 
to 0.4 ml and combining with clip placement, will be expected to improve the 
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TABLE 1 Clinicopathological characteristics of patients 
 




Age y (median[range]) 60 (31-88) 51 (34-78) 
Body mass index (median[range]) 28.8 (19.9-49.6) 30.7 (22.0-39.5) 
Node positive on biopsy at presentation 43 (49) 18 (82) 
Breast surgery   
Wide local excision 42 (48) 6 (27) 
Mastectomy 45 (51) 15 (68) 
No breast surgery 1 (1) 1 (5) 
Axillary Surgery   
Sentinel node biopsy 44 (50) 4 (18) 
Technique   
Isotope and blue dye 41 (93) 3 (75) 
Isotope only 0 1 (25) 
Blue dye only 3 (7) 0 
Sentinel node identified   
Yes  42 (95) 4 (100) 
No 2 (5) 0  
No. of nodes removed with SNB, 
(median [range]) 
2 (1-4) 2 (1-3) 
Axillary lymph node dissection 44 (50) 18 (82) 
Pathology tumour size mm (median 
[range]) 
27 (0-135) 18 (0-102) 
Multifocal or multicentric tumours 21 (24) 6 (27)  
Tumour grade   
I 7 (8) 1 (5) 
II 38 (44) 11 (50) 
III 43 (49) 8 (36) 
Not known 0 2 (9) 
Tumour histology   
Invasive ductal 58 (66) 15 (68) 
Invasive lobular 15 (17) 1 (5) 
Other (mixed, tubular, mucinous, 
medullary, papillary) 
15 (17) 4 (18) 
Not known 0 2 (9) 
Lymphovascular invasion   
Present 39 (44) 7 (32) 
Absent 42 (48) 10 (45) 
Uncertain or not known 7 (8) 5 (23) 
ER status   
Positive 72 (82) 12 (54) 
Negative 15 (17) 9 (41) 
Not known 1 (1) 1 (5) 
PR status   
Positive 54 (61) 8 (36) 
Negative 21 (24) 6 (27) 
Not known 13 (15) 8 (36) 





Positive 16 (18) 8 (36) 
Negative 71 (81) 13 (59) 





TABLE 2 Tattooing results 
 
 




Timing of injection of dye    
At the time of FNA or core biopsy 59 (67) 16 (73) 
Separate visit  29 (33) 6 (27) 
Volume of dye injected ml 
(median[range]) 
1.9 (0.2-4.2) 2.0 (1.0-4.2) 
Site/s of injection of dye   
cortex, perinodal tissue, needle 
tract 
6 (7) 2 (9) 
cortex and perinodal tissue 82 (93) 20 (91) 
Tattoo to surgery months (median[range]) 0.9 (0.1-7.5) 6.5 (2.5-9.2) 
Tattooed node identified 76 (86) 14 (64) 
Sentinel node biopsy 36/44 (82) 3/4 (75) 
Tattooed node was the sentinel 
node 
28 (78) 3 (100) 
Axillary lymph node dissection 40/44 (91) 11/18 (61) 
Number of tattooed nodes  (median[range]) 1 (0-6) 1 (0-6) 
Presence of diffuse black staining of 
axillary tissue at the time of surgery 


























































































































Two surgeons had zero percent identification rate of the tattooed node (0 of 1 total 
cases performed, 0 of 2 total cases performed) 
